Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Peak Bio Inc. is a clinical-stage biopharmaceutical company, which engages in the commercialization of therapeutics that aim to address the medical need of patients with inflammatory, rare and specialty diseases, and cancer. It focuses on the development of treatment of alpha-1 antitrypsin (AAT) deficiency (AATD), a genetic disorder that may result in lung disease or liver disease. The company is headquartered in Palo Alto, CA.
No news articles found for Ignyte Acquisition Corp..
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.